Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry

Elisa Gremese, Gianfranco Ferraccioli, Luca Iaccarino, Elena Bartoloni, Linda Carli, Fulvia Ceccarelli, Fabrizio Conti, Salvatore De Vita, Mauro Galeazzi, Mariele Gatto, Roberto Gerli, Marcello Govoni, Annamaria Iuliano, Elena Mansutti, Gabriella Moroni, Marta Mosca, Cecilia Nalli, Carla Naretto, Melissa Padovan, Lavinia PalmaFrancesca Raffiotta, Dario Roccatello, Angela Tincani, Guido Valesini, Margherita Zen, Andrea Doria

Risultato della ricerca: Contributo in rivistaArticolo in rivista

61 Citazioni (Scopus)

Abstract

To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.
Lingua originaleEnglish
pagine (da-a)449-456
Numero di pagine8
RivistaCLINICAL AND EXPERIMENTAL RHEUMATOLOGY
Volume33
Stato di pubblicazionePubblicato - 2015

Keywords

  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Dose-Response Relationship, Drug
  • Drug Monitoring
  • Drug Resistance
  • Immunosuppression
  • Lupus Erythematosus, Systemic
  • Middle Aged
  • Off-Label Use
  • Remission Induction
  • Rituximab
  • Severity of Illness Index
  • Treatment Outcome

Fingerprint

Entra nei temi di ricerca di 'Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry'. Insieme formano una fingerprint unica.

Cita questo